Hepatic resection after down-staging of unresectable hepatic colorectal metastases

Surg Oncol Clin N Am. 2003 Jan;12(1):211-20, xii. doi: 10.1016/s1055-3207(02)00085-6.

Abstract

Half of the patients with colorectal cancer present with liver metastases at some point in their illness. Surgical resection, which offers the only chance of long-term survival, is an option in only 15% of patients at presentation. Novel chemotherapeutic treatments have enabled approximately 15% of those patients initially deemed inoperable to be down-staged to a point where surgery becomes an option. This aggressive approach, which requires close collaboration between surgeons and oncologists, results in a 40% 5-year survival rate, which is similar to that of patients operated without neoadjuvant chemotherapy. The hope for the future is the development of more effective chemotherapeutic regimens, which may allow more previously unresectable patients to benefit from curative surgery. This article reviews the literature and major areas of progress in treatments for unresectable colorectal cancer.

Publication types

  • Review

MeSH terms

  • Antimetabolites, Antineoplastic / therapeutic use*
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / pathology
  • Colorectal Neoplasms / surgery*
  • Fluorouracil / therapeutic use*
  • Hepatectomy
  • Humans
  • Liver Neoplasms / drug therapy*
  • Liver Neoplasms / secondary
  • Liver Neoplasms / surgery*
  • Neoadjuvant Therapy*
  • Neoplasm Staging
  • Survival Analysis

Substances

  • Antimetabolites, Antineoplastic
  • Fluorouracil